Hubei Jumpcan Pharmaceutical Co., Ltd. (SHA:600566)

SHA:600566 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	7,119	7,997	9,638	8,976	7,618	6,151
Other Revenue	20.38	20.38	16.51	19.87	13	14.25
Revenue	7,140	8,017	9,655	8,996	7,631	6,165
Revenue Growth (YoY)	-26.16%	-16.96%	7.32%	17.90%	23.77%	-11.17%
Cost of Revenue	1,560	1,666	1,784	1,537	1,277	1,130
Gross Profit	5,580	6,350	7,871	7,459	6,354	5,035
Selling, General & Admin	2,965	3,387	4,379	4,477	4,031	3,300
Research & Development	431.51	444.78	464.4	553.3	523.44	243.75
Other Operating Expenses	105.17	115.38	146.24	138.81	120.9	99.9
Operating Expenses	3,484	3,925	4,987	5,205	4,683	3,650
Operating Income	2,096	2,426	2,884	2,254	1,671	1,385
Interest Expense	-23.23	-27.27	-17.58	-30.41	-34.9	-33.03
Interest & Investment Income	298.72	352.77	357.81	183.21	171.42	83.03
Other Non Operating Income (Expenses)	-92.57	-1.03	-0.83	-1.2	-0.41	-0.58
EBT Excluding Unusual Items	2,279	2,750	3,223	2,405	1,807	1,435
Gain (Loss) on Sale of Investments	94.94	99.2	14.6	-7.32	114.55	20.94
Gain (Loss) on Sale of Assets	0.2	0.2	0.13	5.22	0.65	3.35
Asset Writedown	-0.28	-0.28	-1.09	-0.53	-0.42	-0.77
Other Unusual Items	128.98	128.98	60.42	105.09	28.96	25.37
Pretax Income	2,503	2,978	3,297	2,508	1,950	1,484
Income Tax Expense	371.91	441.54	470.03	336.2	233.22	206.29
Earnings From Continuing Operations	2,131	2,537	2,827	2,172	1,717	1,277
Minority Interest in Earnings	-4.59	-5.15	-4.28	-0.97	1.96	-
Net Income	2,127	2,532	2,823	2,171	1,719	1,277
Net Income to Common	2,127	2,532	2,823	2,171	1,719	1,277
Net Income Growth	-28.91%	-10.32%	30.04%	26.27%	34.60%	-21.30%
Shares Outstanding (Basic)	917	917	916	890	886	835
Shares Outstanding (Diluted)	917	917	916	908	900	835
Shares Change (YoY)	-0.04%	0.08%	0.91%	0.91%	7.82%	2.36%
EPS (Basic)	2.32	2.76	3.08	2.44	1.94	1.53
EPS (Diluted)	2.32	2.76	3.08	2.39	1.91	1.53
EPS Growth	-28.88%	-10.39%	28.87%	25.13%	24.84%	-23.12%
Free Cash Flow	1,518	2,002	3,162	2,377	1,646	1,352
Free Cash Flow Per Share	1.66	2.18	3.45	2.62	1.83	1.62
Dividend Per Share	2.090	2.090	1.300	0.880	0.680	0.450
Dividend Growth	60.77%	60.77%	47.73%	29.41%	51.11%	-63.41%
Gross Margin	78.15%	79.21%	81.52%	82.91%	83.27%	81.67%
Operating Margin	29.36%	30.26%	29.87%	25.05%	21.89%	22.47%
Profit Margin	29.79%	31.58%	29.24%	24.13%	22.53%	20.72%
Free Cash Flow Margin	21.26%	24.97%	32.76%	26.42%	21.57%	21.93%
EBITDA	2,397	2,727	3,185	2,561	1,964	1,666
EBITDA Margin	33.58%	34.01%	32.99%	28.47%	25.74%	27.03%
D&A For EBITDA	301.05	301.08	301.2	307.14	293.13	280.95
EBIT	2,096	2,426	2,884	2,254	1,671	1,385
EBIT Margin	29.36%	30.26%	29.87%	25.05%	21.89%	22.47%
Effective Tax Rate	14.86%	14.83%	14.26%	13.41%	11.96%	13.91%
Revenue as Reported	7,140	8,017	9,655	8,996	7,631	6,165

Updated Oct 25, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.